Tsutomu Sato

Prof. Tsutomu Sato


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TSTsutomu Sato
Tsutomu Sato
ATAyumi Tatekoshi
Ayumi Tatekoshi
KTKohichi Takada
Kohichi Takada
SISatoshi Iyama
Satoshi Iyama
YKYusuke Kamihara
Yusuke Kamihara
CMChikao Morimoto
Chikao Morimoto
Dipeptidyl peptidases (DPPs) are proteolytic enzymes that are ideal therapeutic targets in human diseases. Indeed, DPP4 inhibitors are widely used in clinical practice as anti-diabetic agents. In this paper, we show that DPP4 inhibitors also induced cell death in multiple human myeloma cells. Among five DPP4 inhibitors, only two of them, vildagliptin and saxagliptin, exhibited apparent cytotoxic effects on myeloma cell lines, without any difference in suppression of DPP4 activity. As these two DPP4 inhibitors are known to have off-target effects against DPP8/9, we employed the specific DPP8/9 inhibitor 1G244. 1G244 demonstrated anti-myeloma effects on several cell lines and CD138+ cells from patients as well as in murine xenograft model. Through siRNA silencing approach, we further confirmed that DPP8 but not DPP9 is a key molecule in inducing cell death induced by DPP8/9 inhibition. In fact, the expression of DPP8 in CD38+ cells from myeloma patients was higher than that of healthy volunteers. DPP8/9 inhibition induced apoptosis, as evidenced by activated form of PARP, caspases-3 and was suppressed by the pan-caspase inhibitor Z-VAD-FMK. Taken together, these results indicate that DPP8 is a novel therapeutic target for myeloma treatment.

14 December 2016 in Oncology Letters
Verified
Journal Article
Open access
PDF file
AHAkio Higuchi
Akio Higuchi
TOTakashi Oshima
Takashi Oshima
KYKazue Yoshihara
Kazue Yoshihara
KSKentaro Sakamaki
Kentaro Sakamaki
TAToru Aoyama
Toru Aoyama
MMMunetaka Masuda
Munetaka Masuda
Overall survival remains unsatisfactory in stage II/III gastric cancer, even after curative surgery and adjuvant chemotherapy. Platelet-derived growth factor receptor-β (PDGFR-β) is associated with the proliferation of cancer cells. The present study therefore investigated the association of PDGFR-β gene expression with patient outcome in 134 stage II/III gastric cancer patients who received adjuvant chemotherapy with S-1. Relative PDGFR-β gene expression was measured in surgical cancer tissue and adjacent normal mucosa specimens by reverse transcription-quantitative polymerase chain reaction. The PDGFR-β gene expression levels were found to be significantly higher in the cancer tissues compared with the adjacent normal mucosa. A high level of PDGFR-β gene expression was associated with a significantly poorer 5-year overall survival rate compared with a low level of PDGFR-β expression. Upon multivariate analysis, PDGFR-β gene expression was found to be an independent predictor of survival. Overall, the study indicates that PDGFR-β overexpression in gastric cancer tissues is a useful independent predictor of outcome in patients with stage II/III gastric cancer who receive adjuvant chemotherapy with S-1.

1 October 2000 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
SKShinji Kawahito
Shinji Kawahito
TTTamaki Takano
Tamaki Takano
KNKin‐Ichi Nakata
Kin‐Ichi Nakata
TMTomohiro Maeda
Tomohiro Maeda
KNKenji Nonaka
Kenji Nonaka
YNYukihiko Nosé
Yukihiko Nosé

1 March 1994 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
TSTsutomu Sato
Tsutomu Sato
YAYoshihiro Asanuma
Yoshihiro Asanuma
HNHIROSHI NANJO
HIROSHI NANJO
AAAkira Arakawa
Akira Arakawa
TKTomoyuki Kusano
Tomoyuki Kusano
MSMasaaki Shindo
Masaaki Shindo

Verified
Journal Article
Open access
PDF file
SYShota Yonezawa
Shota Yonezawa
THTakayuki Haruki
Takayuki Haruki
KKKeiichi Koizumi
Keiichi Koizumi
ATAKINORI TAKETANI
AKINORI TAKETANI
Yusuke OshimaYusuke Oshima
Yusuke Oshima
SSShigeru Saito
Shigeru Saito
Multiple myeloma (MM) is a cancer of plasma cells. Normal (NL) cells are considered to pass through a precancerous state, such as monoclonal gammopathy of undetermined significance (MGUS), before transitioning to MM. In the present study, we acquired Raman spectra at three stages—834 NL, 711 MGUS, and 970 MM spectra—and applied the dynamical network biomarker (DNB) theory to these spectra. The DNB analysis identified MGUS as the unstable pre-disease state of MM and extracted Raman shifts at 1149 and 1527–1530 cm−1 as DNB variables. The distribution of DNB scores for each patient showed a significant difference between the mean values for MGUS and MM patients. Furthermore, an energy landscape (EL) analysis showed that the NL and MM stages were likely to become stable states. Raman spectroscopy, the DNB theory, and, complementarily, the EL analysis will be applicable to the identification of the pre-disease state in clinical samples.

1 January 1994 in The Journal of Antibiotics
Verified
Journal Article
Open access
TSTsutomu Sato
Tsutomu Sato
MSMitsuyoshi Shibazaki
Mitsuyoshi Shibazaki
HYHiroshi Yamaguchi
Hiroshi Yamaguchi
KAKenji Abe
Kenji Abe
HMHisao Matsumoto
Hisao Matsumoto
MSMinoru Shimizu
Minoru Shimizu